生物製药契约製造市场规模、份额和成长分析（按服务、类型、营运规模、原材料、分子类型和地区）：产业预测（2025-2032）

2023年全球生物製药契约製造市场规模为165亿美元，从2024年的178.5亿美元成长到2032年的335.4亿美元，预测期间（2025-2032年）预计复合年增长率为8.2%。

由于开发新药所需投资的减少、尖端技术的普及以及创新产品的快速进入市场，全球生物製药契约製造市场预计将大幅成长。尤其是，赛默飞世尔科技最近耗资 1.8 亿美元在普莱恩维尔建造的新製造工厂就体现了这一趋势，可以增强额外的生产能力，以满足不断增长的消费者需求。此外，生物加工技术的快速进步正在提高世界各地合约服务提供者的能力，缓解高成本和批次转换问题等传统製造挑战。此外，大公司之间的策略性合併、收购和合资企业正在增加这些服务的潜力，例如 Baxter International 与 Baxter BioPharma Solutions 于 2021 年合作生产 COVID-19 疫苗。

目录

介绍

• 分析目的
• 市场范围
• 定义

分析方法

• 资讯采购
• 次要/主要资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 市场概况及展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考虑因素

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场魅力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术分析
• 监管分析
• 专利分析
• 案例研究
• FDA认证的生物製药CMO中心

全球生物製药契约製造市场规模和复合年增长率：按服务分类（2025-2032）

• 市场概况
• 製造业
• 混炼、填充、整理
• 包装/标籤
• 其他服务

全球生物製药契约製造市场规模和复合年增长率：按类型（2025-2032）

• 市场概况
• 生技药品原料药成分的製造
• 生技药品製品製造

全球生物製药契约製造市场规模及复合年增长率：依营运规模划分（2025-2032）

• 市场概况
• 商业运作
• 临床管理

全球生物製药契约製造市场规模和复合年增长率：按原材料分类（2025-2032）

• 市场概况
• 哺乳动物细胞表现系统
• 非哺乳动物细胞表现系统

全球生物製药契约製造市场规模与复合年增长率：按分子类型划分（2025-2032）

• 市场概况
• 单株抗体
• 细胞/基因治疗
• 抗体药物复合体
• 疫苗
• 治疗性胜肽和蛋白质
• 其他分子类型

全球生物製药契约製造市场规模与复合年增长率：按治疗领域划分（2025-2032）

• 市场概况
• 肿瘤学
• 自体免疫疾病
• 代谢性疾病
• 心血管疾病
• 神经病学
• 感染疾病
• 其他治疗领域

全球生物製药契约製造市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要企业采取的策略
• 近期市场趋势
• 主要企业市场占有率（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• 龙沙（瑞士）
• 赛默飞世尔科技公司（美国）
• 药明生物（中国）
• 康泰伦特公司（美国）
• 三星生物製品（韩国）
• 勃林格殷格翰国际有限公司（德国）
• 富士胶片控股公司（日本）
• 艾伯维公司（美国）
• Eurofins Scientific（卢森堡）
• 金斯瑞生物科技股份有限公司 (中国)
• AGC公司（日本）
• Merck
• KGaA（德国）
• JSR株式会社（日本）
• Stelis（India）
• Recipharm AB（瑞典）
• 紧急（美国）
• 上海復星医药股份有限公司 (中国)
• 乐天生物製品（韩国）
• 海普瑞集团（中国）
• Curia Global, Inc.（美国）

结论和建议

Global Biopharmaceuticals Contract Manufacturing Market size was valued at USD 16.5 billion in 2023 and is poised to grow from USD 17.85 billion in 2024 to USD 33.54 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

The global biopharmaceuticals contract manufacturing market is poised for significant growth, driven by reduced investment needs for new drug development, enhanced access to advanced technologies, and expedited market entry for innovative products. Notably, Thermo Fisher Scientific's recent USD 180 million investment in a new manufacturing facility in Plainville exemplifies this trend, enabling increased production capacity to meet surging consumer demand. Additionally, rapid technological advancements in bioprocessing are alleviating traditional manufacturing challenges, such as high costs and batch changeover issues, boosting the capabilities of contract service providers worldwide. Furthermore, strategic mergers, acquisitions, and joint ventures among key market players are fueling demand for these services, as illustrated by Baxter International's collaboration with Baxter BioPharma Solutions for COVID-19 vaccine production in 2021.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceuticals Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceuticals Contract Manufacturing Market Segmental Analysis

Global Biopharmaceuticals Contract Manufacturing Market is segmented by Service, Type, Scale Of Operation, Source, Molecule Type,TherapeuticArea and region. Based on Service, the market is segmented into Manufacturing, Formulation & Fill-Finish, Packaging & Labeling and Other Services. Based on Type, the market is segmented into Biologic Drug Substance Manufacturing and Biologic Drug Product Manufacturing. Based on Scale Of Operation, the market is segmented into Commercial Operations and Clinical Operations. Based on Source, the market is segmented into Mammalian Expression Systems and Non-Mammalian Expression Systems. Based on Molecule Type, the market is segmented into Monoclonal Antibodies, Cell & Gene Therapies, Antibody-Drug Conjugates, Vaccines, Therapeutic Peptides & Proteins and Other Molecule Types. Based on Therapeutic Area, the market is segmented into Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Neurology, Infectious Diseases and Other Therapeutic Areas. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biopharmaceuticals Contract Manufacturing Market

The global biopharmaceuticals contract manufacturing market is primarily driven by the surging demand for biological therapies, which is influenced by several key factors. Notably, the continual rise in the demand for generics, coupled with heightened research and development efforts and investments in cutting-edge technologies, is expected to propel market growth during the forecast period. Additionally, the expansion of the nuclear medicine sector and a greater focus on specialty medicines are anticipated to further stimulate market progression. These elements collectively contribute to a promising landscape for the biopharmaceuticals contract manufacturing market in the years ahead.

Restraints in the Global Biopharmaceuticals Contract Manufacturing Market

The global biopharmaceuticals contract manufacturing market is facing several restraints that hinder its growth during the forecast period. Key challenges include labeling and packaging complications, along with sterilization issues that complicate the manufacturing process. Furthermore, a general lack of consumer trust combined with insufficient knowledge regarding the manufacturing processes may further restrict market expansion in the upcoming years. These various associated problems are critical factors that stakeholders need to address in order to facilitate smoother operations and enhance market performance in the highly competitive biopharmaceuticals landscape.

Market Trends of the Global Biopharmaceuticals Contract Manufacturing Market

The Global Biopharmaceuticals Contract Manufacturing market is witnessing a notable trend driven by technological advancements, particularly the integration of artificial intelligence (AI). In recent years, the surge in scientific exploration aimed at addressing critical health challenges has propelled market expansion. AI's burgeoning role in analyzing patient symptoms and facilitating real-time data tracking for disease patterns is revolutionizing manufacturing processes. This technological synergy not only enhances efficiency but also fosters innovation in drug development, leading to improved therapeutic solutions. As a result, stakeholders can anticipate robust growth opportunities in the biopharmaceutical contract manufacturing sector in the foreseeable future.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies
• FDA Approved Biopharmaceuticals CMOs Centers

Global Biopharmaceuticals Contract Manufacturing Market Size by Service & CAGR (2025-2032)

• Market Overview
• Manufacturing
• Formulation & Fill-Finish
• Packaging & Labeling
• Other Services

Global Biopharmaceuticals Contract Manufacturing Market Size by Type & CAGR (2025-2032)

• Market Overview
• Biologic Drug Substance Manufacturing
• Biologic Drug Product Manufacturing

Global Biopharmaceuticals Contract Manufacturing Market Size by Scale Of Operation & CAGR (2025-2032)

• Market Overview
• Commercial Operations
• Clinical Operations

Global Biopharmaceuticals Contract Manufacturing Market Size by Source & CAGR (2025-2032)

• Market Overview
• Mammalian Expression Systems
• Non-Mammalian Expression Systems

Global Biopharmaceuticals Contract Manufacturing Market Size by Molecule Type & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Cell & Gene Therapies
• Antibody-Drug Conjugates
• Vaccines
• Therapeutic Peptides & Proteins
• Other Molecule Types

Global Biopharmaceuticals Contract Manufacturing Market Size by Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Oncology
• Autoimmune Diseases
• Metabolic Diseases
• Cardiovascular Diseases
• Neurology
• Infectious Diseases
• Other Therapeutic Areas

Global Biopharmaceuticals Contract Manufacturing Market Size & CAGR (2025-2032)

• North America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • US
  • Canada
• Europe (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JSR Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stelis (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Fosun Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lotte Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepalink Group (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations